How to maintain an adherence to oral anticoagulant in a patient with atrial fibrillation?
https://doi.org/10.18087/cardio.2019.11.n724
Abstract
Less onerous, compared with warfarin, treatment with direct oral anticoagulants (DOA) can lead to better adherence to treatment of patients with atrial fibrillation (AF). However, in a certain number of patients with AF, who were recommended by DOA, cardioembolic stroke recurs, which is largely due to the patients’ failure to comply with medical recommendations. The appointment of DOA as first-line drugs does not guarantee a high adherence of patients with non-valvular AF. For elderly and old patients with AF and numerous comorbidities, the proposal of a simpler pharmacotherapy regimen is especially important. In a number of large modern studies performed in clinical practice, high adherence to rivaroxaban therapy has been established, which may be a result of taking this DOA 1 time per day, its safety and effectiveness.
About the Author
S. G. Kanorskii
Kuban State Medical University
Russian Federation
Russian Federation
Kanorskii Sergey G. – MD, professor
Krasnodar
References
1. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019 Jan 21. doi: 10.1016/j.jacc.2019.01.011. [Epub ahead of print]
2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210.
3. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528. doi: 10.1161/CIR.0000000000000659.
4. Bunch TJ, Gersh BJ. Rhythm control strategies and the role of antiarrhythmic drugs in the management of atrial fibrillation: focus on clinical outcomes. J Gen Intern Med. 2011;26(5):531-537. doi: 10.1007/s11606-010-1574-8.
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. doi: 10.1056/NEJMoa0905561.
6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. doi: 10.1056/NEJMoa1009638.
7. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. doi: 10.1056/NEJMoa1107039.
8. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104. doi: 10.1056/NEJMoa1310907.
9. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-1393. doi: 10.1093/eurheartj/ehy136.
10. Shinoda N, Mori M, Tamura S, Korosue K, Kose S, Kohmura E. Risk of Recurrent Ischemic Stroke with Unintended Low-Dose Oral Anticoagulant Therapy and Optimal Timing of Review. J Stroke Cerebrovasc Dis. 2018;27(6):1546-1551. doi: 10.1016/j.jstrokecerebrovasdis.2018.01.002.
11. Rodriguez RA, Carrier M, Wells PS. Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation? J Thromb Haemost. 2013;11(2):390-394. doi: 10.1111/jth.12086.
12. McHorney CA, Crivera C, Laliberté F, Germain G, Wynant W, Lefebvre P. Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users. PLoS One. 2018;13(4):e0194099. doi: 10.1371/journal.pone.0194099.
13. Alberts MJ, Peacock WF, Fields LE, Bunz TJ, Nguyen E, Milentijevic D et al. Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. Int J Cardiol. 2016;215:11-13. doi: 10.1016/j.ijcard.2016.03.212.
14. Madhavan M, Yao X, Sangaralingham LR, Asirvatham SJ, Friedman PA, McLeod CJ et al. Ischemic Stroke or Systemic Embolism After Transseptal Ablation of Arrhythmias in Patients With Cardiac Implantable Electronic Devices. J Am Heart Assoc. 2016;5(4):e003163. doi: 10.1161/JAHA.115.003163.
15. Borne RT, O'Donnell C, Turakhia MP, Varosy PD, Jackevicius CA, Marzec LN et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovasc Disord. 2017;17(1):236. doi: 10.1186/s12872-017-0671-6.
16. Deshpande CG, Kogut S, Laforge R, Willey C. Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants. Curr Med Res Opin. 2018;34(7):1285-1292. doi: 10.1080/03007995.2018.1428543.
17. Gellad WF, Thorpe CT, Steiner JF, Voils CI. The myths of medication adherence. Pharmacoepidemiol Drug Saf. 2017;26(12):1437-1441. doi: 10.1002/pds.4334.
18. Spivey CA, Liu X, Qiao Y, Mardekian J, Parker RB, Phatak H et al. Stroke associated with discontinuation of warfarin therapy for atrial fibrillation. Curr Med Res Opin. 2015;31(11):2021-2029. doi: 10.1185/03007995.2015.1082995.
19. Hurtado-Navarro I, García-Sempere A, Rodríguez-Bernal C, Santa-Ana-Tellez Y, Peiró S, Sanfélix-Gimeno G. Estimating Adherence Based on Prescription or Dispensation Information: Impact on Thresholds and Outcomes. A Real-World Study With Atrial Fibrillation Patients Treated With Oral Anticoagulants in Spain. Front Pharmacol. 2018;9:1353. doi: 10.3389/fphar.2018.01353.
20. Maura G, Pariente A, Alla F, Billionnet C. Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study. Pharmacoepidemiol Drug Saf. 2017;26(11):1367-1377. doi: 10.1002/pds.4268.
21. Tsai K, Erickson SC, Yang J, Harada AS, Solow BK, Lew HC. Adherence, persistence, and switching patterns of dabigatran etexilate. Am J Manag Care. 2013;19(9):e325-332. PMID:24449962
22. Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J. 2014;167(6):810-817. doi: 10.1016/j.ahj.2014.03.023.
23. Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016;18(8):1150-1157. doi: 10.1093/europace/euv421.
24. Shore S, Ho PM, Lambert-Kerzner A, Glorioso TJ, Carey EP, Cunningham F et al. Site-level variation in and practices associated with dabigatran adherence. JAMA. 2015;313(14):1443-1450. doi: 10.1001/jama.2015.2761.
25. Thorne K, Jayathissa S, Dee S, Briggs N, Taylor J, Reid S et al. Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice. Intern Med J. 2014;44(3):261-265. doi: 10.1111/imj.12370.
26. Yamada K, Nabeshima T. Pharmacist-managed clinics for patient education and counseling in Japan: current status and future perspectives. J Pharm Health Care Sci. 2015;1:2. doi: 10.1186/s40780-014-0001-4.
27. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691-705. doi: 10.1111/j.1365-2125.2012.04167.x.
28. Finkelman BS, French B, Bershaw L, Kimmel SE. Factors affecting time to maintenance dose in patients initiating warfarin. Pharmacoepidemiol Drug Saf. 2015;24(3):228-236. doi: 10.1002/pds.3735.
29. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772-779. doi: 10.1016/j.ahj.2007.12.011.
30. Mochari H, Ferris A, Adigopula S, Henry G, Mosca L. Cardiovascular disease knowledge, medication adherence, and barriers to preventive action in a minority population. Prev Cardiol. 2007;10(4):190-195. PMID:17917515
31. Song X, Sander SD, Varker H, Amin A. Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation. Am J Cardiovasc Drugs. 2012;12(4):245-253. doi: 10.2165/11632540-000000000-00000.
32. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497. PMID:16079372
33. Johnson ME, Lefèvre C, Collings SL, Evans D, Kloss S, Ridha E et al. Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. BMJ Open. 2016;6(9):e011471. doi: 10.1136/bmjopen-2016-011471.
34. Collings SL, Lefèvre C, Johnson ME, Evans D, Hack G, Stynes G et al. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany. PLoS One. 2017;12(10):e0185642. doi: 10.1371/journal.pone.0185642.
35. Sørensen R, Jamie Nielsen B, Langtved Pallisgaard J, Ji-Young Lee C, Torp-Pedersen C. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists. Eur Heart J Cardiovasc Pharmacother. 2017;3(3):151-156. doi: 10.1093/ehjcvp/pvw048.
36. Lip GYH, Pan X, Kamble S, Kawabata H, Mardekian J, Masseria C et al. Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban. PLoS One. 2018;13(4):e0195950. doi: 10.1371/journal.pone.0195950.
37. Raparelli V, Proietti M, Cangemi R, Lip GY, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2017;117(2):209-218. doi: 10.1160/TH16-10-0757.
38. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119-125. PMID:16818816
39. Andrade JG, Krahn AD, Skanes AC, Purdham D, Ciaccia A, Connors S. Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. Can J Cardiol. 2016;32(6):747-753. doi: 10.1016/j.cjca.2015.09.023.
40. Rosanio S, Keylani AM, D'Agostino DC, DeLaughter CM, Vitarelli A. Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. Int J Cardiol. 2014;174(3):471-483. doi: 10.1016/j.ijcard.2014.04.179.
41. Rivard L, Khairy P. Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation. Can J Cardiol. 2017;33(12):1556-1564. doi: 10.1016/j.cjca.2017.09.024.
42. Diener HC, Hart RG, Koudstaal PJ, Lane DA, Lip GYH. Atrial Fibrillation and Cognitive Function: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(5):612-619. doi: 10.1016/j.jacc.2018.10.077.
43. Rydén L, Zettergren A, Seidu NM, Guo X, Kern S, Blennow K et al. Atrial fibrillation increases the risk of dementia amongst older adults even in the absence of stroke. J Intern Med. 2019 Mar 20. doi: 10.1111/joim.12902. [Epub ahead of print]
44. Conen D, Rodondi N, Müller A, Beer JH, Ammann P, Moschovitis G et al. Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2019;73(9):989-999. doi: 10.1016/j.jacc.2018.12.039.
45. Desai NR, Krumme AA, Schneeweiss S, Shrank WH, Brill G, Pezalla EJ et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. Am J Med. 2014;127(11):1075-1082.e1. doi: 10.1016/j.amjmed.2014.05.013.
46. Forslund T, Wettermark B, Hjemdahl P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin Pharmacol. 2016;72(3):329-338. doi: 10.1007/s00228-015-1983-z.
47. Yao X, Abraham NS, Alexander GC, Crown W, Montori VM, Sangaralingham LR et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016;5(2). pii: e003074. doi: 10.1161/JAHA.115.003074.
48. Kim H, Lee YS, Kim TH, Cha MJ, Lee JM, Park J et al. A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF). Korean J Intern Med. 2019 Apr 25. doi: 10.3904/kjim.2017.415. [Epub ahead of print]
49. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015;17(4):514-523. doi: 10.1093/europace/euu311.
50. Kreutz R, Persson PB, Kubitza D, Thelen K, Heitmeier S, Schwers S et al. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study. J Thromb Haemost. 2017;15(10):2017-2028. doi: 10.1111/jth.13801.
51. Brown JD, Shewale AR, Talbert JC. et al. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data. J Manag Care Spec Pharm. 2017;23(9):958-967. doi: 10.18553/jmcp.2017.23.9.958.
52. Crivera C, Nelson WW, Bookhart B, Martin S, Germain G, Laliberté F et al. Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. Curr Med Res Opin. 2015;31(10):1889-1895. doi: 10.1185/03007995.2015.1077213.
53. McHorney CA, Ashton V, Laliberté F, Germain G, Wynant W, Crivera C et al. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm. 2017;23(9):980-988. doi: 10.18553/jmcp.2017.23.9.980.
54. Emren SV, Zoghi M, Berilgen R, Özdemir İH, Çelik O, Çetin N et al. Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study. Bosn J Basic Med Sci. 2018;18(2):185-190. doi: 10.17305/bjbms.2017.2279.
55. Deshpande CG, Kogut S, Willey C. Real-World Health Care Costs Based on Medication Adherence and Risk of Stroke and Bleeding in Patients Treated with Novel Anticoagulant Therapy. J Manag Care Spec Pharm. 2018;24(5):430-439. doi: 10.18553/jmcp.2018.24.5.430.
56. Brown JD, Shewale AR, Talbert JC. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm. 2016;22(11):1319-1329. PMID:27783556
57. McHorney CA, Peterson ED, Ashton V, Laliberté F, Crivera C, Germain G et al. Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients. Curr Med Res Opin. 2019;35(4):653-660. doi: 10.1080/03007995.2018.1530205.
58. Weeda ER, Coleman CI, McHorney CA, Crivera C, Schein JR, Sobieraj DM. Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: A meta-regression analysis. Int J Cardiol. 2016;216:104-109. doi: 10.1016/j.ijcard.2016.04.082.
59. Martinez BK, Baker WL, Sood NA, Bunz TJ, Meinecke AK, Eriksson D et al. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation. Pharmacotherapy. 2019;39(2):196-203. doi: 10.1002/phar.2213.
60. Coleman CI, Peacock WF, Bunz TJ, Alberts MJ. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke. 2017;48(8):2142-2149. doi: 10.1161/STROKEAHA.117.017474.
61. Staerk L, Gerds TA, Lip GYH, Ozenne B, Bonde AN, Lamberts M et al. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. J Intern Med. 2018;283(1):45-55. doi: 10.1111/joim.12683.
62. Jacobs MS, Schouten JF, de Boer PT, Hoffmann M, Levin LÅ, Postma MJ. Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands. Curr Med Res Opin. 2018;34(10):1839-1847. doi: 10.1080/03007995.2018.1459528.
63. Rossi AP, Facchinetti R, Ferrari E, Nori N, Sant S, Masciocchi E et al. Predictors of self-reported adherence to direct oral anticoagulation in a population of elderly men and women with non-valvular atrial fibrillation. J Thromb Thrombolysis. 2018;46(2):139-144. doi: 10.1007/s11239-018-1679-1.
64. Hecker J, Marten S, Keller L, Helmert S, Michalski F, Werth S et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2016;115(5):939-949. doi: 10.1160/TH15-10-0840.
65. Kirchhof P, Radaideh G, Kim YH, Lanas F, Haas S, Amarenco P et al. Global Prospective Safety Analysis of Rivaroxaban. J Am Coll Cardiol. 2018;72(2):141-153. doi: 10.1016/j.jacc.2018.04.058.
Review
For citations:
Kanorskii S.G. How to maintain an adherence to oral anticoagulant in a patient with atrial fibrillation? Kardiologiia. 2019;59(11):76-83. (In Russ.) https://doi.org/10.18087/cardio.2019.11.n724
Views:
1097
Email this article 
Post a Comment 
